Full Text View
Tabular View
No Study Results Posted
Related Studies
Trial of VLTS-589 in Subjects With Intermittent Claudication
This study has been completed.
First Received: September 8, 2003   Last Updated: June 23, 2005   History of Changes
Sponsor: Valentis
Information provided by: Valentis
ClinicalTrials.gov Identifier: NCT00068133
  Purpose

The purpose of this study is to evaluate the safety and tolerability of VLTS-589 compared with placebo, administered bilaterally to the lower extremities, in subjects with intermittent claudication and to determine the effect of VLTS-589 in peak walking time (PWT) for subjects receiving VLTS-589 compared with subjects receiving placebo.


Condition Intervention Phase
Intermittent Claudication
Peripheral Vascular Disease
Gene Transfer: Plasmid based Gene Transfer product-VLTS-589
Phase II

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study
Official Title: A Phase II Multicenter, Double-Blind, Placebo-Controlled, Trial of VLTS-589 in Subjects With Intermittent Claudication Secondary to Peripheral Arterial Disease

Resource links provided by NLM:


Further study details as provided by Valentis:

Estimated Enrollment: 100
Study Start Date: June 2003
Estimated Study Completion Date: June 2005
  Eligibility

Ages Eligible for Study:   40 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Men or women between 40 and 80 years of age,
  • Must give informed consent,
  • Current medical history of peripheral arterial disease, which includes the following symptoms: leg pain, leg discomfort or leg weakness

Exclusion criteria:

  • Ulcers or gangrene,
  • History of cancer (except skin cancer) within the past 5 years,
  • Participation in another clinical trial within 30 days of enrollment in this trial,
  • Unwillingness or inability to comply with all study requirements
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00068133

  Show 20 Study Locations
Sponsors and Collaborators
Valentis
  More Information

No publications provided

Study ID Numbers: VLTS-589-121
Study First Received: September 8, 2003
Last Updated: June 23, 2005
ClinicalTrials.gov Identifier: NCT00068133     History of Changes
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Arterial Occlusive Diseases
Signs and Symptoms
Peripheral Vascular Diseases
Vascular Diseases
Intermittent Claudication
Cardiovascular Diseases
Arteriosclerosis

ClinicalTrials.gov processed this record on November 09, 2009